bluebird bio

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Bluebird bio reports strong financials and plans for expansion

Bluebird bio demonstrated financial strength and successful gene therapy launches.
Challenges include potential submission delay and operational complexities.
Opportunities lie in expanding patient demand, optimizing strategies, and exploring international markets.
Overall, Bluebird bio remains confident in its products and market positioning.

Bluebird bio excels in gene therapy market, faces manufacturing challenges

Bluebird bio is making significant strides in gene therapy, with successful commercial launches and a strong financial position.
Challenges lie in adapting to a different manufacturing process for lovo-cel and ensuring operational efficiency for future launches.
Opportunities abound in expanding commercial reach, leveraging expertise for targeted launches, and strategic decision-making on PRV monetization.

Bluebird bio reports revenue growth and milestones in Q3

Bluebird bio's Q3 performance showed revenue growth and positive momentum in key product launches.
The company faces challenges related to safety concerns, manufacturing issues, and analyst inquiries.
Strengths lie in a well-established commercial infrastructure and strategic pricing approach.
Opportunities include financing plans, potential voucher sale, and expansion of treatment centers.

bluebird bio reports revenue growth and eyes U.S. expansion opportunities

bluebird bio's Q4 performance showed revenue growth and extended cash runway
Strengths lie in commercial progress, multibillion-dollar U.S. opportunity, and margin improvement
Challenges include financial restatement, reimbursement dynamics, and Medicaid coverage
Opportunities exist in ex U.S. markets, expansion plans, and optimizing reimbursement strategies

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV), if received, in connection with the potential approval of lovotibeglogene autotemcel (lovo-cel) for sickle cell disease. Under the terms of the agreement, rights to the PRV will transfer to the buyer and the Company will receive $103 million upon closing of the sale, which is.

bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss third quarter 2023 financial results and business updates on Tuesday, November 7 at 8:00 a.m. ET. To access the call via telephone, please register at this link https://edge.media-server.com/mmc/p/cq4tzukh to receive a dial in number and unique PIN to access the live conference call. The live webcast of the call may be accessed by visiting the “Events & Presen.

bluebird bio to Host Third Quarter 2023 Financial Results Conference Call

CM Life Sciences III

Virgin Galactic

Are you looking for the best penny stocks to buy now? Today might be your day

Best Penny Stocks To Buy Now? These 3 Are Moving Fast In October

ARK Genomic Revolution Multi-Sector ETF

ARK Innovation ETF

Beam Therapeutics

CRISPR Therapeutics

Pfizer

Vertex Pharmaceuticals

In September, Cathie Wood and Ark Invest bought shares of Beam Therapeutics more than a dozen times. Beam Therapeutics is a clinical-stage drugmaker with a unique approach to developing new gene therapies.

Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?

Bluebird Bio should make progress with its two approved therapies in the next year. It could also launch another one, which is under review for approval, by early 2024.

Where Will Bluebird Bio Be in 1 Year?

Biogen

BioMarin Pharmaceutical

Editas Medicine

Intellia Therapeutics

Novartis

Regeneron Pharmaceuticals

Solid Biosciences

Sarepta Therapeutics

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASDAQ: SRPT, which are developing gene therapies. ‘

Are Gene Therapy Stocks The Market's Next Big Winners?

CRISPR Therapeutics and Bluebird Bio each have potential growth catalysts coming in the next 12 months. CRISPR Therapeutics has a powerful ally and plenty of cash.

Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio

Gilead Sciences

Many gene-editing biotechs are developing cures. Curing patients is good.

1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know

Bluebird Bio and CRISPR Therapeutics are unprofitable companies focused on gene editing. However, both biotechs are on the verge of winning important regulatory approvals.

More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics

Recursion Pharmaceuticals

The consensus price target for Recursion Pharmaceuticals suggests the stock can soar 88% from recent prices. The average analyst estimates for bluebird bio stock imply a gain of 99% over the next 12 months.

2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?

Bluebird (BLUE) Up 7.3% Since Last Earnings Report: Can It Continue?

Bluebird Bio is strapped for cash, and a lot of must-do spending is coming up. It will likely need to scale up its clinic footprint while also launching a new medicine.

Is Bluebird Bio a Bargain Buy in September?

Bluebird Bio expects to learn the regulatory fate of its sickle cell disease candidate later this year. If approved, the biotech might become a top buyout target.

Wall Street Thinks This Tiny Biotech Company Could Soar Soon

Amgen

Caterpillar

Cisco Systems

Chevron

Dow Inc

Erasca Inc

Intel

iShares Russell 2000 ETF

Johnson & Johnson

McDonald's

Walmart

Two new sample Breakout Stocks for Week 35 curated by the MDA model for a 10% short-term upside along with a Dow pick. The Momentum Gauges, S&P 500 Gauges, and Weekly Gauges all continue negative after the longest positive signal since March 2021 on the weekly gauges. Last week three of the four picks gained over the 10% mark, closing up an average of +9.17% for the week with strong Segment 6 momentum.

August MDA Breakout Stocks Week 35 - 2023: High-Frequency Gainers To Give You An Edge

Bluebird Bio has two approved gene-editing treatments, but they aren't generating much sales yet. The small-cap biotech company could earn another approval by the end of the year.

1 Beaten-Down Growth Stock You'd Regret Not Buying on the Dip, According to Wall Street

Exact Sciences

Microsoft

Novavax

Rivian Automotive

Roku

Super Micro Computer

The Nasdaq has taken a rather large hit in recent weeks, sinking about 7.5% between July 18 and Aug 17. Two of the main reasons for the decline are worries about U.S. inflation and the Chinese economy.

7 Very Oversold Nasdaq Stocks to Buy Right Now

bluebird (BLUE) announces that its gene therapy, lovotibeglogene autotemcel, developed for sickle cell disease, will not be scheduled for advisory committee meeting, thereby accelerating the path for approval.

bluebird's (BLUE) Lovo-cel to Not Face Advisory Committee

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has communicated that an advisory committee meeting will not be scheduled for lovotibeglogene autotemcel (lovo-cel). Lovo-cel is a potentially transformative one-time gene therapy for individuals living with sickle cell disease (SCD) with a proposed indication for patients ages 12 and older who have a history of vaso-occlusive events (VOEs). The Agency previousl.

bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease

bluebird bio (BLUE) reports better-than-expected results in the second quarter of 2023 due to product revenues now being generated from Skysona (elivaldogene autotemcel) and Zynteglo (betibeglogene autotemcel).

bluebird (BLUE) Q2 Earnings Top, Zynteglo & Skysona Fuel Revenues

Inozyme Pharma, Inc.

Protalix Biotherapeutics

Sabre

Penny stocks are shares of companies trading for under $5. They generally are the stock of companies in early or development stages that are typically smaller in size.

Top Penny Stocks To Buy? 4 To Watch Under $5

Bluebird Bio (BLUE) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.29 per share a year ago.

Bluebird Bio (BLUE) Reports Q2 Loss, Misses Revenue Estimates

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported financial results and business highlights for the second quarter ended June 30, 2023, including recent commercial and operational progress, and regulatory updates. "As we approach the anniversaries of the FDA approvals of ZYNTEGLO and SKYSONA, we have continued to advance our commercial strategy and prove the model for the gene therapy field on our path to profitability,” said.

bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress

Arista Networks

Growth stocks have returned to form after a poor showing in 2022. Bluebird Bio and Arista Networks stand out as two of the more compelling buys in the growth stock landscape right now.

2 Magnificent Growth Stocks I'm Buying Hand Over Fist Right Now

Bluebird's approved gene-editing therapies have a limited combined market opportunity. However, the company could launch another one within a year.

1 Beaten-Down Stock That Could Soar by 89%, According to Wall Street

Etsy

Rigel Pharmaceuticals

While the idea of making it big with the winning lottery ticket sounds appealing to practically anybody, the reality is that you're better off targeting stocks with high returns. Don't get me wrong – this segment of the capital market presents incredible risks.

3 Stocks to Buy for Lottery Jackpot Style Returns

News for bluebird bio Stock (BLUE)